Warmuth Markus 4

What Happened
Markus Warmuth, President & CEO and a director of Monte Rosa Therapeutics (GLUE), sold 8,000 shares on April 14, 2026. The filing reports a weighted average sale price of $17.64 per share for total proceeds of $141,125. This was a sale (disposition) — sales are often routine liquidity events and do not necessarily indicate a change in company prospects.

Key Details

• Transaction date: 2026-04-14 (reported on Form 4 filed 2026-04-15).
• Price: weighted average $17.64 per share; individual trades ranged $17.64–$17.65 (see footnote).
• Quantity: 8,000 shares sold; proceeds reported as $141,125.
• Shares owned after the transaction: not disclosed in the information provided in this summary (see the Form 4 for full beneficial ownership).
• Footnote: the Column 4 price is a weighted average; the filer will provide breakdown of sales at each price on request.
• Timeliness: filing appears timely (filed one day after the reported transaction date).

Context
This was an outright sale (S code) reported on a Form 4. For retail investors, purchases generally carry more direct signaling value than routine insider sales, which can reflect diversification or personal financial planning. Check the full Form 4 for any additional holdings, prior 10b5-1 plans, or related transactions that could provide more context.